BioLight Signed a Non-Binding MOU for a License Option in the Glaucoma Field

BioLight signed a non-binding Memorandum of Understanding between the company and an American company, engaged in the discovery and development of pharmaceuticals and medical devices and innovative treatment for glaucoma, for an Ocular implant for sustained release of drugs.

Under the MOU, the American company will give, through a subsidiary company a worldwide exclusive option for an exclusive license, for use of the implant technology, including research and development, commercialization, production, distribution, marketing, sales and services.

Link to the complete article

Link to Newsroom

Comments are closed.